Recalled Medicines & supplements – Current GIS Alerts 2026
Found 700 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
TRANXENE 20
A quality defect was identified: potential presence of visible particles in solvent ampoules of a product intended for preparation of an injectable solution. Potential effects: complications after intravenous administration, embolism, inflammatory reactions, lack of treatment safety.
AVONEX
Suspected quality defect of the immediate packaging of the specified batches, which may result in loss of tightness and a potential risk to patients’ health or life. Potential effects: infections, complications after administration of a non-sterile drug, lack of treatment efficacy.
RANIC
Contamination of the medicinal product with trace amounts of N-nitrosodimethylamine (NDMA) in the ranitidine-containing solution for injection. Potential effects: carcinogenic and toxic effects, possible health risk.
RANITYDYNA AUROVITAS
Exceedance of the acceptable limit of N-nitrosodimethylamine (NDMA) contamination was detected and confirmed in products containing Ranitidinum, creating a real, high probability of a threat to patients’ health or life. Potential effects: chronic exposure, carcinogenic effects, liver damage, general poisoning of the body.
PALIN
The European Medicines Agency decision concerned serious adverse reactions of some quinolone and fluoroquinolone antibiotics; the benefit-risk balance of products containing pipemidic acid is no longer favorable. Potential effects: serious adverse reactions, complications, risk to health or life.
MEGAPAR FORTE
An error in the leaflet incorrectly specifies the maximum dose, which may lead to overdose and poses a real risk to patients’ health or life. Potential effects: paracetamol poisoning, liver damage, serious complications, life‑threatening condition.
APHTIN
Non-compliant product odor and a decrease in active substance content were found, not meeting quality specifications. Potential effects: lack of treatment efficacy, possible adverse effects related to product degradation.
SYMBELLA
The product does not meet specification requirements for the amount of ethinylestradiol released within 15 minutes, which may affect contraceptive efficacy. Potential effects: reduced effectiveness, risk of unplanned pregnancy.
SOLVERTYL
Suspicion of the presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products with Ranitidinum, which may affect human health and life and poses a potential risk to patients. Potential effects: poisoning, carcinogenic effects, systemic complications.
RIFLUX
Suspected presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products containing ranitidine, which may affect human health and life due to the potential toxic effects of this substance. Potential effects: possible toxic effects, complications, health risk.
RANITYDYNA AUROVITAS
Suspected presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products containing Ranitidinum, which may affect human health and life, posing a potential risk to patients. Potential effects: poisoning, carcinogenic effects, serious health complications.
RANIMAX TEVA
The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in this medicinal product, which may affect human health and life. Potential effects: increased risk of carcinogenic effects and serious threat to patients’ health and life.
RANIGAST
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic effect, liver damage, other toxic complications.
RANIGAST
The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic and other toxic effects, risk to health and life.
RANIGAST FAST
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic effects and other serious health disorders.
RANIC
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product containing ranitidine, which may affect human health and life. Potential effects: possible carcinogenic effects, liver damage, poisoning.
RANIBERL MAX
Suspected presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: carcinogenic action, organ damage with long-term exposure.
RANIGAST PRO
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: poisoning, carcinogenic effects.
RANIGAST MAX
The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life and potentially endanger patients’ life or health. Potential effects: carcinogenic effects, liver damage, other toxic effects.
BICAVERA Z 1,5% GLUKOZĄ I WAPNIEM 1,25 MMOL/L
Potential quality defect of the primary packaging, which may affect the safety and quality of the peritoneal dialysis solution. Potential effects: complications during dialysis, infections, lack of treatment efficacy.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.